Bevacizumab for neovascular age-related macular degeneration in China

Ophthalmology

Volumn 119, Issue 10, 2012, Pages 2087-2093

  Li, Xiaoxin ^a,b   Hu, Yonghua ^c   Sun, Xiaodong ^d   Zhang, Junjun ^e   Zhang, Maonian ^f  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e SICHUAN UNIVERSITY   (China)

^f CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHINA; CONTROLLED STUDY; EYE EXAMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHINA; COLORING AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84867100056     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.05.016     Document Type: Article

References (20)

1. Z.Q. Wu, J.E. Cao Epidemiological survey of senile macular degeneration [in Chinese] Zhonghua Yan Ke Za Zhi 28 1992 246 247
2. G.H. Guan, Y.J. Zhan Epidemiological survey of age-related macular degeneration [in Chinese] Zhonghua Yan Di Bing Za Zhi 5 1989 208 212
3. M.G. He, J.J. Xu, K.L. Wu Epidemiological survey of age-related macular degeneration in Doumen county of Guangdong province [in Chinese] Zhonghua Yan Di Bing Za Zhi 10 1994 115 116
4. H.D. Zou, X. Zhang, X. Xu Prevalence study of age-related macular degeneration in Caojiadu blocks, Shanghai [in Chinese] Zhonghua Yan Ke Za Zhi 41 2005 15 19
5. H.D. Zou, N. Wang A prevalence survey of blindness and visual impairment in adults aged equal or more than 60 years in Beixinjing blocks of Shanghai, China [in Chinese] Zhonghua Yan Ke Za Zhi 45 2009 786 792
6. S. Michels, P.J. Rosenfeld, C.A. Puliafito Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study Ophthalmology 112 2005 1035 1047
7. A.A. Moshfeghi, P.J. Rosenfeld, C.A. Puliafito Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study [report online] Ophthalmology 113 2006 2002.e112
8. P.J. Rosenfeld, A.A. Moshfeghi, C.A. Puliafito Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 36 2005 331 335
9. R.M. Rich, P.J. Rosenfeld, C.A. Puliafito Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Retina 26 2006 495 511
10. R.L. Avery, D.J. Pieramici, M.D. Rabena Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 2006 363 372
11. J. Mordenti, R.A. Cuthbertson, N. Ferrara Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration Toxicol Pathol 27 1999 536 544
12. T.U. Krohne, N. Eter, F.G. Holz, C.H. Meyer Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans Am J Ophthalmol 146 2008 508 512
13. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
14. A. Tufail, P.J. Patel, C. Egan ABC Trial Investigators Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study [report online] BMJ 340 June 2010 2459 http://www.bmj.com/ content/340/bmj.c2459?view=long&pmid=20538634 Accessed March 16, 2012
15. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
16. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
17. A. Tsujikawa, S. Ooto, K. Yamashiro Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab Jpn J Ophthalmol 54 2010 310 319
18. M.H. Song, H.W. Ryu, Y.J. Roh One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy Ophthalmologica 226 2011 119 126
19. S.R. Nalluri, D. Chu, R. Keresztes Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2008 2277 2285
20. Antiplatelet Trialists' Collaboration Collaborative overview of randomized trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106